Literature DB >> 12351960

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

Gilbert Greub1, Alessandro Cozzi-Lepri, Bruno Ledergerber, Schlomo Staszewski, Luc Perrin, Veronica Miller, Patrick Francioli, Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, Enos Bernasconi, Huldrych F Günthard, Bernard Hirschel, Andrew N Phillips, Amalio Telenti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12351960     DOI： 10.1097/00002030-200209270-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  41 in total

1.  Monitoring of HIV type 1 DNA load and drug resistance in peripheral blood mononuclear cells during suppressive antiretroviral therapy does not predict virologic failure.

Authors:  Ingrid A Beck; Minyoung Jang; Jennifer McKernan-Mullin; Marta Bull; Thor Wagner; Sharon Huang; Lin-Ye Song; Sharon Nachman; Paul Krogstad; Susan H Eshleman; Andrew Wiznia; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-27       Impact factor: 2.205

Review 2.  Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature.

Authors:  Albert M L Anderson; John A Bartlett
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

3.  HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL.

Authors:  Yumi Mitsuya; Mark A Winters; W Jeffrey Fessel; Soo-Yon Rhee; Sally Slome; Jason Flamm; Michael Horberg; Leo Hurley; Daniel Klein; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

5.  Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.

Authors:  Jonathan Z Li; Sebastien Gallien; Tri D Do; Jeffrey N Martin; Steven Deeks; Daniel R Kuritzkes; Hiroyu Hatano
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

6.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Authors:  Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

7.  Intermittent HIV-1 viremia (blips) and virological failure in a cohort of people living with HIV from São Paulo, Brazil.

Authors:  Karim Yaqub Ibrahim; Patricia Recordon-Pinson; Denis Malvy; Hervé Fleury; Aluisio Cotrim Segurado
Journal:  AIDS Patient Care STDS       Date:  2012-09       Impact factor: 5.078

8.  The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).

Authors:  R Kanapathipillai; H McManus; D D Cuong; O T Ng; N V Kinh; M Giles; T Read; I Woolley
Journal:  HIV Med       Date:  2014-01-26       Impact factor: 3.180

Review 9.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

10.  Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Authors:  Libin Rong; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2009-10-16       Impact factor: 4.475
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.